lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-16. Anything still debated is marked as such rather than presented as settled.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
This type of enzymes presents two binding sites: the substrate of the enzyme and the effectors. Effectors are small molecules which modulate the enzyme activity; they function through reversible, non-covalent binding of a regulatory metabolite in the allosteric site (which is not the active site). When bound, these metabolites do not participate in catalysis directly, but they are still essential: they lead to conformational changes in a concrete part of the enzyme. These changes affect the overall conformation of the active site, causing modifications on the activity of the reaction. Properties Allosteric enzymes are generally larger in mass than other enzymes. Different from having a single subunit enzyme, in this case they are composed of multiple subunits, which contain active sites and regulatory molecule binding sites. They present a special kinetics: the cooperation. In here, configuration changes in each chain of the protein strengthen changes in the other chains. These changes occur at the tertiary and quaternary levels of organisation. Based on modulation, they can be classified in two different groups:
Culver's soon shifted its attention to developing markets beyond the Midwest, and opened the first franchise outside the region in Texas in February 1998. The current franchising strategy is one of strategic expansion. The chain expanded into Colorado Springs, Colorado and Cheyenne, Wyoming in 2005, followed by an opening in Bowling Green, Kentucky in July 2006. Locations traditionally had a 120-seat format through much of Culver's expansion. The Metro-98 prototype was developed in 2006 and first constructed in Fort Dodge, Iowa. While the new layout has less seating to offer guests, it also reduced the amount of land needed for construction by around 20%. The company expanded to the Phoenix metropolitan area in 2008. The first franchise in Utah opened in Midvale in 2011, when a couple from Wisconsin relocated there. They signed a development agreement for four locations in the southern half of Salt Lake County. By the end of 2011, 445 Culver's restaurants were open in 19 states. They opened in South Carolina in 2012; Florida, Georgia, and Tennessee in 2014; and North Carolina in 2015. A location was announced for Alabama in June 2018, and expansion continued into Arkansas in January 2022. In February 2026, Culver's announced plans to enter the Virginia market, starting with their first location in the Richmond area.
Seventeen yachts and 167 crew started the first race of 27,500 nmi (50,900 km), which began from Portsmouth, United Kingdom, on 8 September 1973. Approximately 3000 spectator boats set out to witness the historic start. The first race was won by Mexican amateur Ramón Carlín in a Swan 65 yacht, Sayula II. Sayula II was followed by Adventure, Grand Louis and Kriter. The original course was designed to follow the route of the square riggers, which had carried cargo around the world during the 19th Century. From 2001 the ownership of the race was taken over by Volvo and Volvo Cars and the race was renamed the 'Volvo Ocean Race'. Stopover ports were added in Germany, France, and Sweden being Volvo's three biggest car markets in Europe. Winning the race does not attract a cash prize, as the feat of competing is presented as sufficient reward. Many of the crew in the Volvo Ocean Race race crew other professional teams in other high-profile events, such as the Olympic Games, Sydney to Hobart Yacht Race, the America's Cup, or the Fastnet Race. The worst weather conditions are usually encountered in the Southern Ocean where waves sometimes top 150 feet (46 m) and winds can reach 70 knots (130 km/h). The 2017–18 race covered 45,000 nautical miles, which is the longest route in its history.
=== Appeal === In January 2024, Letby applied to the Court of Appeal for permission to challenge her convictions, but this was refused by a single judge. She renewed her application, and at a three‑day hearing in April 2024 her legal team advanced four grounds of appeal relating to the trial judge's rulings. In May 2024, a panel comprising Dame Victoria Sharp, Lord Justice Holroyde and Mrs Justice Lambert refused permission to appeal. As part of the appeal, Letby's counsel, Ben Myers, again challenged the admission of evidence from paediatrician Evans, arguing that it should have been excluded on the basis that Evans had been "dogmatic and biased". The appeal judges rejected this, finding that Evans did not lack impartiality, was suitably qualified to give expert evidence, and that it was for the jury to assess its weight. A second ground of appeal concerned the medical evidence relating to alleged fatal air injections, which the defence described as "very weak". A third ground argued that the trial judge had erred in directing the jury that they could convict even if they were uncertain about the precise method used in each case. The final ground alleged that the judge had failed to investigate a question of juror impartiality. All four grounds were dismissed, with the Court concluding in its written judgement that the trial had been "thoughtful, fair, comprehensive and correct" and that none of the challenges raised by the defence were "arguable".
Sources: en.wikipedia.org
Laboratory mice Dogs Big cats Horses Cattle Chickens Bananaquit Gyrfalcon Kermode bears Rock pocket mice Domestic rabbits Antarctic fur seals Mammoth A study on unrelated British and Irish individuals demonstrated that over 80% of people with red hair and/or fair skin that tan poorly have a dysfunctional variant of the MC1R gene. This is compared to less than 20% in people with brown or black hair, and less than 4% in people showing a good tanning response. Asp294His (rs1805009) is a single nucleotide polymorphism (SNP) in the MC1R gene and it is associated with red hair and light skin type. Other SNPs in the gene, Arg151Cys and Arg160Trp, are also associated with red hair. The Out-of-Africa model proposes that modern humans originated in Africa and migrated north to populate Europe and Asia. These migrants most likely had a functional MC1R variant and, accordingly, dark hair and skin as displayed by indigenous Africans today. As humans migrated north, the absence of high levels of solar radiation in northern Europe and Asia relaxed the selective pressure on active MC1R, allowing the gene to mutate into dysfunctional variants without reproductive penalty, then propagate by genetic drift. Studies show the MC1R Arg163Gln allele has a high frequency in East Asia and may be part of the evolution of light skin in East Asian populations. No evidence is known for positive selection of MC1R alleles in Europe and there is no evidence of an association between the emergence of dysfunctional variants of MC1R and the evolution of light skin in European populations.
== History == Two of the drug's three components were originally developed at the Public Health Agency of Canada's National Microbiology Laboratory (NML), and a third at the U.S. Army Medical Research Institute of Infectious Diseases; the cocktail was optimized by Gary Kobinger, then branch chief of the NML, and is undergoing further development by Leaf Biopharmaceutical (LeafBio, Inc.), a San Diego–based arm of Mapp Biopharmaceutical. LeafBio created ZMapp in collaboration with its parent and Defyrus Inc., each of which had licensed its own cocktail of antibodies, called MB-003 and ZMab.
Suitable computer and biological viruses already exist in the Pico Vault, an ultrasecure storage on the Moon, used for the most dangerous agents of these kinds. The Europa team also agree to leave a petabyte-capacity holographic 3D storage medium on Europa to allow Halman and other lifeforms in the monolith to upload themselves and escape the monolith's failure. The monolith does receive orders to exterminate humanity, and starts a duplication, whereupon millions of monoliths form two cascade screens to prevent Solar light and heat from reaching Earth and its colonies, but the monoliths all quickly disintegrate as a result of the virus. The monoliths' makers' response to its destruction will occur in another 900 years as the earliest possibility. The petabyte storage device, containing Halman and other lifeforms, but also infected with the virus, is subsequently sealed by scientists in the Pico Vault. At the close of the story, Poole and other humans land on Europa to start peaceful relations with the primitive native Europans. A statement is made that the monolith's makers will not determine humanity's fate until "the Last Days". A chronological continuation can be considered the short epilogue of the second book, 2010: Odyssey Two (1982), in which the action takes place 17,000 years later, in 20,001 CE (see more details).
Sources: en.wikipedia.org
A few commercially available food supplements include meso-zeaxanthin in their formulations, supposedly to support macular health. A 2016 study comparing the carotenoid concentrations of commercially available food supplements on their label found that, while only two declared their inclusion of meso-zeaxanthin, it was present in several others as well. The authors concluded that the presence of meso-zeaxanthin in the other formulations was likely due to it being less expensive than zeaxanthin, and it is hard to distinguish from one from the other via chemical analysis.
The result of this extensive procedure was still not a pure protein, but it produced a limited number of bands by SDS-PAGE, and one band of 46 kilodaltons was found to correlate in intensity with the enzymatic activity. This band was cut from the gel and digested with trypsin, and peptides from it were separated from one another by reverse phase high performance liquid chromatography. The resulting fragments were then microsequenced by an automated Edman degradation. Three corresponded to vimentin, an intermediate filament protein of 56 kDa believed to be a contaminant, and the other two matched the cDNA clone subsequently identified as NAPE-PLD. Once this clue had been obtained, the identification could be confirmed by a less onerous procedure: Overexpression of the putative NAPE-PLD cDNA in COS-7 cells yielded a strong NAPE-PLD enzymatic activity, whose characteristics were shown to be similar to those of the original heart extract.
Neely's articles have been compiled into several books, including, The Secret History of Knoxville (1995), From the Shadow Side (2003), and Knoxville: This Obscure Prismatic City (2009). Arcadia has published several short books on local topics as part of its "Images of America" series, including Ed Hooper's WIVK (2008) and WNOX (2009), and 1982 World's Fair (2009) by Martha Rose Woodward. Other books on Knoxville topics include Wendy Lowe Besmann's Separate Circle: Jewish Life in Knoxville, Tennessee, which details the development of the city's Jewish community, and Sylvia Lynch's Harvey Logan in Knoxville (1998), which covers Kid Curry's time in the city. Knoxville native and college professor Dr. Marcy Conway has also written about Knoxville's history in the book The Sunsphere City (2022) coining this nickname for Knoxville as well as mentioning current arts and culture experiences in the area. The Junior League of Knoxville's Knoxville: 50 Landmarks (1976), provides descriptions of various historical buildings in the city. A more detailed overview of the city's architectural development is provided in "Historic and Architectural Resources of Knox County" (1994), a pamphlet written by Metropolitan Planning Commission preservationist Ann Bennett for the National Register of Historic Places. The National Register includes over 100 buildings and districts in Knoxville and Knox County, with extensive descriptions of the buildings provided in their respective nomination forms, which are being digitized for the Register's online database.
== Overview == Developmental bioelectricity is a sub-discipline of biology, related to, but distinct from, neurophysiology and bioelectromagnetics. Developmental bioelectricity refers to the endogenous ion fluxes, transmembrane and transepithelial voltage gradients, and electric currents and fields produced and sustained in living cells and tissues. This electrical activity is often used during embryogenesis, regeneration, and cancer suppression—it is one layer of the complex field of signals that impinge upon all cells in vivo and regulate their interactions during pattern formation and maintenance. This is distinct from neural bioelectricity (classically termed electrophysiology), which refers to the rapid and transient spiking in well-recognized excitable cells like neurons and myocytes (muscle cells); and from bioelectromagnetics, which refers to the effects of applied electromagnetic radiation, and endogenous electromagnetics such as biophoton emission and magnetite.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.